Dimerix Assumes Sponsorship of US IND for New Asset DMX-652
Open PDF
| Stock | Dimerix Ltd (DXB.ASX) |
|---|---|
| Release Time | 17 Aug 2026, 8:38 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
Dimerix Secures U.S. IND for New Asset DMX-652
Key Points
- Dimerix acquired DMX-652, a Phase 2-ready renal asset
- Successful transfer of U.S. IND sponsorship to Dimerix
- DMX-652 set for Phase 2 trial in acute kidney injury
Full Summary
Dimerix Limited (ASX: DXB) has announced the acquisition of DMX-652, a Phase 2-ready renal asset, and successfully completed the transfer of its U.S. Investigational New Drug (IND) sponsorship from Mission Therapeutics. DMX-652, a selective inhibitor of USP30, is designed to support mitochondrial quality control in injured kidney cells. The asset is set to enter a Phase 2 clinical trial for acute kidney injury (AKI) associated with cardiac surgery. The transfer of the IND represents a significant milestone, providing Dimerix with direct control over clinical development activities in the U.S. DMX-652 has shown promising pre-clinical data and encouraging safety and pharmacokinetic data from Phase 1 trials.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In